Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CU4Q
|
|||
| Former ID |
DNC002824
|
|||
| Drug Name |
S-Methylcysteine
|
|||
| Synonyms |
7728-98-5; H-DL-Cys(Me)-OH; H-D-HoCys-OH; S-Methyl-DL-cysteine; USAF CB-24; Methylcysteine; 2-amino-3-(methylsulfanyl)propanoic acid; 19651-44-6; 1-carboxy-2-methylthioethylamine; Methylcysteine, L-; ALANINE, 3-(METHYLTHIO)-, L-; EINECS 231-787-0; Methylcysteine #; S-Methyl cysteine; DL-S-Methylcysteine; DL-S-Methyl-Cys-OH; DL-Cysteine, S-methyl-; AC1Q5S9H; AC1L5E8F; SCHEMBL110459; ACMC-209a03; IDIDJDIHTAOVLG-UHFFFAOYSA-; CTK0E0884; IDIDJDIHTAOVLG-UHFFFAOYSA-N; MolPort-003-876-437; NSC15387; NSC-15387; AKOS022154885
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H9NO2S
|
|||
| Canonical SMILES |
CSCC(C(=O)O)N
|
|||
| InChI |
1S/C4H9NO2S/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1
|
|||
| InChIKey |
IDIDJDIHTAOVLG-VKHMYHEASA-N
|
|||
| CAS Number |
CAS 1187-84-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
79282, 7643760, 9379529, 10505204, 30428765, 51075718, 57400064, 78659331, 85087672, 85174908, 87691564, 91642138, 92298510, 103848494, 104745457, 113479200, 117543602, 119523205, 125338973, 125662000, 126427285, 126521895, 128151609, 134989510, 142302408, 162284694, 162445139, 164846814, 165734156, 215754288, 226483854, 249506103, 249926561, 251901369, 252147442, 252266047
|
|||
| ChEBI ID |
CHEBI:45658
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin D (CTSD) | Target Info | Inhibitor | [1] |
| O-6-methylguanine-DNA-alkyltransferase (MGMT) | Target Info | Inhibitor | [1] | |
| BioCyc | Thyroid hormone biosynthesis | |||
| KEGG Pathway | Sphingolipid signaling pathway | |||
| Lysosome | ||||
| Tuberculosis | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | LKB1 signaling events | |||
| Ceramide signaling pathway | ||||
| Direct p53 effectors | ||||
| Validated nuclear estrogen receptor alpha network | ||||
| Reactome | Collagen degradation | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | DNA Damage Reversal | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.